Your browser doesn't support javascript.
loading
Development of the Pulmonary Hypertension Functional Classification Self-Report: a patient version adapted from the World Health Organization Functional Classification measure.
Highland, Kristin B; Crawford, Rebecca; Classi, Peter; Morrison, Ross; Doward, Lynda; Nelsen, Andrew C; Castillo, Howard; Mathai, Stephen C; DuBrock, Hilary M.
  • Highland KB; Cleveland Clinic, Cleveland, OH, USA.
  • Crawford R; RTI Health Solutions, The Pavilion, Towers Business Park, Wilmslow Road, Didsbury, Manchester, M20 2LS, UK. rcrawford@rti.org.
  • Classi P; United Therapeutics, Durham, NC, USA.
  • Morrison R; RTI Health Solutions, The Pavilion, Towers Business Park, Wilmslow Road, Didsbury, Manchester, M20 2LS, UK.
  • Doward L; RTI Health Solutions, The Pavilion, Towers Business Park, Wilmslow Road, Didsbury, Manchester, M20 2LS, UK.
  • Nelsen AC; United Therapeutics, Durham, NC, USA.
  • Castillo H; United Therapeutics, Durham, NC, USA.
  • Mathai SC; Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • DuBrock HM; Mayo Clinic, Rochester, MN, USA.
Health Qual Life Outcomes ; 19(1): 202, 2021 Aug 24.
Article en En | MEDLINE | ID: mdl-34429110
ABSTRACT

BACKGROUND:

Pulmonary arterial hypertension (PAH) is characterized by progressive limitations on physical activity, right heart failure, and premature death. The World Health Organization functional classification (WHO-FC) is a clinician-rated assessment used widely to assess PAH severity and functioning, but no equivalent patient-reported version of PAH symptoms and activity limitations exists. We developed a version of the WHO-FC for self-completion by patients the Pulmonary Hypertension Functional Classification Self-Report (PH-FC-SR).

METHODS:

Semistructured interviews were conducted with three health care providers (HCPs) via telephone to inform development of the draft PH-FC-SR. Two rounds of semi-structured interviews were conducted with 14 US patients with a self-reported PAH diagnosis via telephone/online to elicit concepts and iteratively refine the PH-FC-SR.

RESULTS:

HCPs reported that the WHO-FC was a useful tool for evaluating patients' PAH severity over time and for making treatment decisions but acknowledged that use of the measure is subjective. Patients in round 1 interviews (n = 6) reported PAH symptoms, including shortness of breath (n = 6), fatigue (n = 5), syncope (n = 5), chest pains (n = 3), and dizziness (n = 3). Round 1 patients identified challenges with the original WHO-FC, including comprehensibility of clinical terms and overlapping descriptions of class II and III, and preferred the Draft 1 PH-FC-SR over the original WHO-FC. After minor changes were made to Draft 2, round 2 interviews (n = 8) confirmed patients understood the PH-FC-SR class descriptions, interpreting them consistently.

CONCLUSIONS:

The HCP and patient interviews identified and confirmed certain limitations inherent within the clinician-rated WHO-FC, including subjective assessment and overlapping definitions for class II and III. The PH-FC-SR includes patient-appropriate language, symptoms, and physical activity impacts relevant to patients with PAH. Future research is recommended to validate the PH-FC-SR and explore its correlation with the physician-assessed WHO-FC and other outcomes.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Calidad de Vida / Hipertensión Pulmonar Tipo de estudio: Prognostic_studies / Qualitative_research Límite: Humans Idioma: En Año: 2021 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Calidad de Vida / Hipertensión Pulmonar Tipo de estudio: Prognostic_studies / Qualitative_research Límite: Humans Idioma: En Año: 2021 Tipo del documento: Article